Schulze-Koops H, Kalden J R
Department of Internal Medicine III, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
Arthritis Res. 2000;2(5):337-41. doi: 10.1186/ar108. Epub 2000 Jun 29.
The substantial progress in our understanding of molecular and cellular biology has allowed us to design biological therapeutics ('biologicals') with defined targets and effector functions. These biologicals have greatly contributed to our current knowledge of pathogenetic mechanisms in autoimmune diseases. However, although some of the biologicals have been extremely successful in treating the symptoms of chronic inflammation, biological therapy has not yet met the expectations of permanently silencing the chronic immune response. In this commentary we discuss current concepts and future directions of biological therapy, and the potential usefulness of biologicals as a treatment of human autoimmune diseases in appropriate critical applications with the use of suitably designed agents.
我们对分子和细胞生物学理解的重大进展使我们能够设计出具有明确靶点和效应功能的生物疗法（“生物制剂”）。这些生物制剂极大地促进了我们目前对自身免疫性疾病发病机制的认识。然而，尽管一些生物制剂在治疗慢性炎症症状方面极其成功，但生物疗法尚未达到永久抑制慢性免疫反应的预期。在这篇评论中，我们讨论了生物疗法的当前概念和未来方向，以及在适当的关键应用中使用精心设计的药物时，生物制剂作为治疗人类自身免疫性疾病的潜在效用。
